ORIGINAL ARTICLE
Fascin overexpression is associated with higher grades of breast cancer
1
Department of Pathology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
2
Firoozabadi Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
3
Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran
Submission date: 2019-01-22
Final revision date: 2019-09-08
Acceptance date: 2019-10-15
Publication date: 2020-03-06
Pol J Pathol 2019;70(4):264-268
KEYWORDS
TOPICS
ABSTRACT
In the present study, we tried to evaluate the relationship between Fascin molecule expression and other histopathologic parameters, especially tumor grade and hormone profile. Sixty-one malignant breast tumors were enrolled in this study. Fascin marker staining was performed on paraffin blocks of breast samples using immunohistochemistry (IHC) method. The age range of patients was 26-87 years, with an average of 48.41 ±1.68. Our results showed that fascin expression was significantly higher in tumors with high grade histology, lymph node involvement and larger tumor size (p = 0.04, 0.04, 0.04, respectively). Also fascin expression in triple negative tumors was significantly higher than other molecular subtypes (p = 0.001). fascin can be used as an important marker in evaluating breast cancer especially in triple negative tumors.
REFERENCES (27)
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
2.
Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev 2016; 17: 47-52.
3.
DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64: 52-62.
4.
Zahmatkesh B, Keramat A, Alavi N, et al. Breast cancer trend in Iran from 2000 to 2009 and prediction till 2020 using a trend analysis method. Asian Pac J Cancer Prev 2016; 17: 1493-1498.
5.
DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67: 439-448.
6.
Jayo A, Parsons M. Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biol 2010; 42: 1614-1617.
8.
Zhao J, Zhou Y, Zhang Z, et al. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Cancer Lett 2010; 290: 238-247.
9.
Piskor BM, Pryczynicz A, Lubowicka E, et al. Immunohistochemical expression of Fascin-1 in colorectal cancer in relation to clinical and pathological parameters. Folia Histochem Cytobiol 2018; 1: 106-112.
10.
Zheng HC, Zhao S. The meta and bioinformatics analysis of fascin expression in gastric cancer: a potential marker for aggressiveness and worse prognosis. Oncotarget 2017; 8: 105574.
11.
Park SH, Song JY, Kim YK, et al. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol 2014; 44: 637-646.
12.
Lee HJ, An HJ, Kim TH, et al., Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients. J Cancer 2017; 8: 3122-3129.
13.
Min KW, Chae SW, Kim DH, et al. Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett 2015; 10: 121-130.
14.
Erdoğan G, Peştereli HE, Çolak T, et al. Fascin expression in invasive ductal carcinoma of breast. Turk J Pathol 2010; 26: 130-135.
15.
Esnakula AK, Ricks-Santi L, Kwagyan J, et al., Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women. J Clin Pathol 2014; 67: 153-160.
16.
Iqbal BM, Buch A. Hormone receptor (ER, PR, HER2/neu) status and proliferation index marker (Ki-67) in breast cancers: Their onco-pathological correlation, shortcomings and future trends. Medical Journal of Dr. DY Patil University 2016; 9: 674.
17.
Kondov B, Milenkovikj Z, Kondov G, et al. Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients. Open Access Maced J Med Sci 2018; 6: 961-967.
18.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
19.
Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 2016; 17 (S3): 43-46.
20.
Duncan MW, et al. Biomarkers for Diagnosis of Breast Cancer 2011, Google Patents.
21.
Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017; 75: 284-298.
22.
Wang CQ, Tang CH, Chang HT, et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med 2016; 5: 1983-1988.
23.
Tsuchiya H, Sasaki A, Tsunoda Y, et al. Fascin is Expressed in Basal-Liketype Triple Negative Breast Cancer Associated with High Malignant Potential in Japanese Women. Int J Cancer Clin Res 2015; 2: 035.
24.
Youssef NS, Hakim SA. Association of Fascin and matrix metalloproteinase-9 expression with poor prognostic parameters in breast carcinoma of Egyptian women. Diagn Pathol 2014; 9: 136.
25.
Al-Alwan M, Olabi S, Ghebeh H, et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PloS One 2011; 6: e27339.
26.
Grothey A, Hashizume R, Sahin AA, et al. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 2000; 83: 870-873.
27.
Kureishy N, Sapountzi V, Prag S, et al. Fascins, and their roles in cell structure and function. Bioessays 2002; 24: 350-361.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
